Vicki B Benard1, Philip E Castle2, Steven A Jenison3, William C Hunt4, Jane J Kim5, Jack Cuzick6, Ji-Hyun Lee7, Ruofei Du8, Michael Robertson4, Scott Norville3, Cosette M Wheeler4. 1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 3. Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque. 4. House of Prevention Epidemiology (HOPE), Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque. 5. Department of Health Policy and Management, Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 6. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, England. 7. Division of Epidemiology, Biostatistics, and Preventive Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque. 8. University of New Mexico Comprehensive Cancer Center, Albuquerque.
Abstract
IMPORTANCE: A substantial effect of human papillomavirus (HPV) vaccines on reducing HPV-related cervical disease is essential before modifying clinical practice guidelines in partially vaccinated populations. OBJECTIVE: To determine the population-based cervical intraepithelial neoplasia (CIN) trends when adjusting for changes in cervical screening practices that overlapped with HPV vaccination implementation. DESIGN, SETTING, AND PARTICIPANTS: The New Mexico HPV Pap Registry, which captures population-based estimates of both cervical screening prevalence and CIN, was used to compute CIN trends from January 1, 2007, to December 31, 2014. Under New Mexico Administrative Code, the New Mexico HPV Pap Registry, a statewide public health surveillance program, receives mandatory reporting of all cervical screening (cytologic and HPV testing) and any cervical, vulvar, and vaginal histopathological findings for all women residing in New Mexico irrespective of outcome. MAIN OUTCOME MEASURES: Prespecified outcome measures included low-grade CIN (grade 1 [CIN1]) and high-grade CIN (grade 2 [CIN2] and grade 3 [CIN3]). RESULTS: From 2007 to 2014, a total of 13 520 CIN1, 4296 CIN2, and 2823 CIN3 lesions were diagnosed among female individuals 15 to 29 years old. After adjustment for changes in cervical screening across the period, reductions in the CIN incidence per 100 000 women screened were significant for all grades of CIN among female individuals 15 to 19 years old, dropping from 3468.3 to 1590.6 for CIN1 (annual percentage change [APC], -9.0; 95% CI, -12.0 to -5.8; P < .001), from 896.4 to 414.9 for CIN2 (APC, -10.5; 95% CI, -18.8 to -1.2; P = .03), and from 240.2 to 0 for CIN3 (APC, -41.3; 95% CI, -65.7 to 0.3; P = .05). Reductions in the CIN2 incidence were also significant for women 20 to 24 years old, dropping from 1027.7 to 627.1 (APC, -6.3; 95% CI, -10.9 to -1.4; P = .02). CONCLUSIONS AND RELEVANCE: Population-level decreases in CIN among cohorts partially vaccinated for HPV may be considered when clinical practice guidelines for cervical cancer screening are reassessed. Evidence is rapidly growing to suggest that further increases in raising the age to start screening are imminent, one step toward integrating screening and vaccination.
IMPORTANCE: A substantial effect of human papillomavirus (HPV) vaccines on reducing HPV-related cervical disease is essential before modifying clinical practice guidelines in partially vaccinated populations. OBJECTIVE: To determine the population-based cervical intraepithelial neoplasia (CIN) trends when adjusting for changes in cervical screening practices that overlapped with HPV vaccination implementation. DESIGN, SETTING, AND PARTICIPANTS: The New Mexico HPV Pap Registry, which captures population-based estimates of both cervical screening prevalence and CIN, was used to compute CIN trends from January 1, 2007, to December 31, 2014. Under New Mexico Administrative Code, the New Mexico HPV Pap Registry, a statewide public health surveillance program, receives mandatory reporting of all cervical screening (cytologic and HPV testing) and any cervical, vulvar, and vaginal histopathological findings for all women residing in New Mexico irrespective of outcome. MAIN OUTCOME MEASURES: Prespecified outcome measures included low-grade CIN (grade 1 [CIN1]) and high-grade CIN (grade 2 [CIN2] and grade 3 [CIN3]). RESULTS: From 2007 to 2014, a total of 13 520 CIN1, 4296 CIN2, and 2823 CIN3 lesions were diagnosed among female individuals 15 to 29 years old. After adjustment for changes in cervical screening across the period, reductions in the CIN incidence per 100 000 women screened were significant for all grades of CIN among female individuals 15 to 19 years old, dropping from 3468.3 to 1590.6 for CIN1 (annual percentage change [APC], -9.0; 95% CI, -12.0 to -5.8; P < .001), from 896.4 to 414.9 for CIN2 (APC, -10.5; 95% CI, -18.8 to -1.2; P = .03), and from 240.2 to 0 for CIN3 (APC, -41.3; 95% CI, -65.7 to 0.3; P = .05). Reductions in the CIN2 incidence were also significant for women 20 to 24 years old, dropping from 1027.7 to 627.1 (APC, -6.3; 95% CI, -10.9 to -1.4; P = .02). CONCLUSIONS AND RELEVANCE: Population-level decreases in CIN among cohorts partially vaccinated for HPV may be considered when clinical practice guidelines for cervical cancer screening are reassessed. Evidence is rapidly growing to suggest that further increases in raising the age to start screening are imminent, one step toward integrating screening and vaccination.
Authors: Elaine W Flagg; S Deblina Datta; Mona Saraiya; Elizabeth R Unger; Edward Peters; Lauren Cole; Vivien W Chen; Thomas Tucker; Mary Jane Byrne; Glenn Copeland; Won Silva; Meg Watson; Hillard Weinstock Journal: Cancer Causes Control Date: 2014-02-28 Impact factor: 2.506
Authors: Linda M Niccolai; Pamela J Julian; James I Meek; Vanessa McBride; James L Hadler; Lynn E Sosa Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-05-23 Impact factor: 4.254
Authors: Eduardo L Franco; Salaheddin M Mahmud; Joseph Tota; Alex Ferenczy; François Coutlée Journal: Arch Med Res Date: 2009-07-25 Impact factor: 2.235
Authors: Jack Cuzick; Orrin Myers; William C Hunt; Michael Robertson; Nancy E Joste; Philip E Castle; Vicki B Benard; Cosette M Wheeler Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-12-03 Impact factor: 4.254
Authors: Susan Hariri; Lauri E Markowitz; Nancy M Bennett; Linda M Niccolai; Sean Schafer; Karen Bloch; Ina U Park; Mary W Scahill; Pamela Julian; Nasreen Abdullah; Diane Levine; Erin Whitney; Elizabeth R Unger; Martin Steinau; Heidi M Bauer; James Meek; James Hadler; Lynn Sosa; Suzanne E Powell; Michelle L Johnson Journal: Emerg Infect Dis Date: 2015-09 Impact factor: 6.883
Authors: Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-31 Impact factor: 17.586
Authors: Michael J Silverberg; Wendy A Leyden; Jennifer O Lam; Steven E Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Karen K Smith-McCune; George F Sawaya Journal: Lancet Child Adolesc Health Date: 2018-08-08
Authors: Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Mei-Chin Hsieh; Elizabeth Van Dyne; Christina Lefante; Jean A Shapiro; Paran Pordell; Mary Anne Lynch; Natalie Gomez; Brent Mumphrey; Lauren Maniscalco; Rachna Jetly-Shridhar; Mona Saraiya; Xiao-Cheng Wu Journal: J Registry Manag Date: 2019
Authors: Karam El-Bayoumy; Neil D Christensen; Jiafen Hu; Raphael Viscidi; Douglas B Stairs; Vonn Walter; Kun-Ming Chen; Yuan-Wan Sun; Joshua E Muscat; John P Richie Journal: Cancer Prev Res (Phila) Date: 2020-05-20
Authors: Nancy M McClung; Julia W Gargano; Nancy M Bennett; Linda M Niccolai; Nasreen Abdullah; Marie R Griffin; Ina U Park; Angela A Cleveland; Troy D Querec; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02-21 Impact factor: 4.254